Company intelligence / Profile preview

Molecules to Medicine Advisory Group

Cambridge, Massachusetts, United Statesrocketreach.co ↗

Ownership: Private
Development stage: Other

Overview

Molecules to Medicine Advisory Group is an active life sciences consulting and advisory firm. The group is led by Alison Schecter, who serves as Chief Executive Officer. Based in Cambridge, MA, the organization provides strategic guidance and expertise for companies operating in the biotech, pharma, and healthcare sectors. There is no evidence that it develops its own therapeutics or technologies[1].

Therapeutic areas: Other
Modalities: Not specified
Industry: Consulting

Beyond the preview

Go deeper on Molecules to Medicine Advisory Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molecules to Medicine Advisory Group.

Explore the full profile